Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.
Press releases published on August 11, 2025
Full Alliance Group’s Qubitera Holdings Expands Quant Blockchain Healthcare Development Roadmap
GlobeNewswire
·
August 11, 2025
TAMPA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) announced today that its subsidiary, Qubitera Holdings Inc., has released a comprehensive five-phase technical roadmap to deploy a post-quantum cryptography (PQC)-based …
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
GlobeNewswire
·
August 11, 2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results …
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 11, 2025
Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have …
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
GlobeNewswire
·
August 11, 2025
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated …
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
GlobeNewswire
·
August 11, 2025
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN-01 demonstrates potential in …
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire
·
August 11, 2025
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 SPECTRA clinical trial in DME …
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2025
GlobeNewswire
·
August 11, 2025
- Se han publicado datos preliminares positivos del estudio de Fase 2b de VIRAGE de VCN-01 (zabilugene almadenorepvec); los datos ampliados se presentarán en el Congreso de la European Society for Medical Oncology (ESMO) de 2025 que tendrá lugar en octubre …
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 11, 2025
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The …
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient in the Phase 1 Study for ARR-217 (MRG007), a CDH17 …
Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
GlobeNewswire
·
August 11, 2025
MINNEAPOLIS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with …
Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
GlobeNewswire
·
August 11, 2025
FORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its …
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
GlobeNewswire
·
August 11, 2025
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median …
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
GlobeNewswire
·
August 11, 2025
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the " …
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
GlobeNewswire
·
August 11, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial …
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride …
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
GlobeNewswire
·
August 11, 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, …
MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will …
Altimmune Board of Directors Appoints Jerry Durso as Chairman
GlobeNewswire
·
August 11, 2025
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) …
Avicanna Announces US Patent and Trademark Office Issuance of New Patent
GlobeNewswire
·
August 11, 2025
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on …
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial …